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Introduction 
Streptococcus pneumoniae (SP) causes significant rates 
of morbidity and mortality around the world, since it 
is one of the main invasive disease aetiological agents 
(meningitis, bacteraemia/sepsis and bacteriemic pneu-
monia), as well as non-bacteriemic pneumonia, reaching 
the highest incidence rates and strongest clinical-health-
care impact in both infants and older people [1, 2]. In 
relation to Community-Acquired Pneumonia (CAP), it 
has been estimated that on average this pathogen ac-
counts for 30% of the cases, a percentage some studies 
have reported to be as high as 50%, which undoubtedly 
outline the SP clinical picture with the highest relative 
frequency and incidence in this population [2].
Despite universal immunisation programmes for children 
using the 7-valent pneumococcal   conjugate vaccine 
(PCV7), available in the USA since 2000, and since 2001 
in Europe, has determined a drastic reduction of invasive 
diseases and, even if to a lesser extent, also CAPs and 
Acute Otitis Media in the target population of the inter-
vention [3, 4], the impact of the pneumococcal disease in 
the adult-older population still remains significant in the 
Western countries. All this notwithstanding: 
(i)  the availability, for several years, of a 23-valent 
anti-pneumococcal polysaccharide vaccine (PPV), 
currently recommended in many countries, includ-
ing Italy, for the vaccination of over 65-year-old 
adults and patients >2 years of age affected by spe-
cific morbid conditions and immunosuppressed;
(ii)  the indirect effect, known as herd protection, of the 
universal programmes of paediatric immunisation 
that has contributed, at least in part, to the reduction 
of invasive diseases even in non-immunised adults 
and older people, due to the direct effect of immu-
nisation clearance of the oropharyngeal carriage of 
the paediatric infection reservoir, with a consequen-
tial reduced transmission of the microbial agent in 
the community [5, 6];
(iii) the well-known difficulty of conducting an aetiologi-
cal assessment of the invasive disease cases and, even 
more, of non-bacteriemic pneumonia, which have 
certainly led to a significant underestimation of the 
global clinical impact of SP in the population [7].
Although the universal immunization programs of 
new-borns have allowed, in the last decade, to obtain 
increasingly detailed scientific evidence on the epidemi-
ology and burden of SP diseases in children, it would 
be appropriate to better focus on these aspects, in the 
adult-older age groups.  In fact, in view of the clinical 
development of a second generation of pneumococcal 
conjugate vaccines (PCV13), with the possibility to be 
used on individuals aged >50 years, defining the epide-
miology and the healthcare and economic impact of SP 
on this population group is particularly important for 
public health decision makers, in order to redefine in the 
short-to-medium term the appropriate vaccine preven-
tion strategies.
Below, we shall briefly describe and discuss (i) some of the 
most interesting epidemiological data available in Western 
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Summary
Streptococcus pneumoniae (SP) is a leading cause of morbid-
ity and mortality worldwide. Despite the availability, since the 
early 1980s, of a 23-valent pneumococcal polysaccharide vaccine 
(PPV23), its recommendation and increased use in the last decades, 
and the indirect benefits against invasive pneumococcal diseases 
following the pediatric immunization strategies with the 7-valent 
pneumococcal conjugate vaccine (PCV7), pneumoccal diseases, 
particularly Community Acquired Pneumonia (CAP), still remain 
a substantial burden among older adults in Western countries. 
The recent availability on the market of a second generation of 
pneumococcal conjugate vaccines, with an enlarged spectrum of 
protection against some serotypes not included in the PCV7 (i.e., 
the 13-valent pneumococcal conjugate vaccine – PCV13), opens 
new interesting perspectives for improving the control of this sig-
nificant health-care issue among the entire population. 
The most interesting and up-dated epidemiological data regard-
ing the impact of SP in adults and the elderly in Western countries, 
together with the available evidence concerning the efficacy and 
effectiveness of the PPV23 in the same population, are reported 
and discussed below.
The full article is free available on www.jpmh.org
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countries regarding the health impact of SP in adults and 
the elderly, with a particular focus on CAPs, and (ii) the 
whole evidence about the efficacy/effectiveness profiles 
of PPV, which has been the only prevention tool available 
against SP for this age group during the last three decades.
Clinical and healthcare impact  
of pneumococcal disease in adults 
If the estimation of the clinical impact of invasive dis-
eases attributable to SP is well-known for its difficulty, it 
is even more difficult when the outcome to measure are 
the CAPs, due to (i) the heterogeneity of these clinical 
pictures, (ii) the poor tendency of physicians to obtain a 
diagnosis confirmed by laboratory tests, (iii) the sub-opti-
mal sensitivity of blood culture, further accentuated by an 
early antibiotic therapy during the initial stages of illness, 
and finally, (iv) the difficulty of having data on incidence 
cases, particularly in the community setting (outpatients 
and domiciliary visits). This is indirectly confirmed by the 
great variability of incidence and mortality data reported 
in the literature regarding the adult population in relation 
to these pathological forms in the last 20 years.
Therefore, some interesting results recently published in 
the literature deserve to be mentioned, which have al-
lowed to better define this important issue in the Ameri-
can, European and Italian context. 
Weycker et al. developed a model capable of obtaining 
a detailed evaluation of the annual clinical and econom-
ic impact of SP diseases in the USA in adults aged ≥50 
years, by analysing the incidence and mortality rates, and 
associated costs, both overall and divided according to 
age brackets and specific clinical risk profiles (e.g. pa-
tients suffering from chronic disease, immunosuppres-
sion, etc.). Therefore, it has been estimated that out of 
91.5 million American adults aged ≥ 50 years, each year 
there are 29,500 cases of pneumococcal invasive disease 
(27,700 cases of bacteraemia and 1,800 cases of menin-
gitis), 502,600 cases of non-bacteriemic pneumococcal 
pneumonia (198,600 cases requiring hospital care and 
304,000 cases treated outside the hospital setting) and 
25,400 deaths associated with pneumococcal disease 
(6,200 due to invasive disease and 19,200 due to pneu-
monia) [2].  In terms of direct and indirect costs, this im-
portant clinical impact has been translated into an annual 
estimation of 3.7 and 1.8 billion dollars respectively, most 
of which (81% direct and 62% indirect) are attributable to 
non-bacteriemic pneumococcal pneumonia [2] (Fig. 1).
Although the older elderly (i.e. those aged ≥ 85 years) ac-
counted for only 6% of the study population, this was the 
group with the highest clinical burden, equal to 19% of 
Fig. 1. impact of pneumococcal diseases on adults aged ≥50 years in usa: cases, deaths and costs (from Weycker et al., 2012 [2], mod.).
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all the cases, 33% of all deaths, and 21% of total direct 
costs. On the contrary, the population group aged between 
50-64 years, accounting for 59% of the older American 
population, had the highest number of cases of pneumo-
coccal disease (28%), as well as the highest total finan-
cial costs (39%) and the highest percentage of indirect 
financial costs (69%). Finally, in relation to the evalua-
tion of outcomes in high-risk individuals (i.e. about 16% 
of adult Americans aged >50 years) accounted for the 
highest number of cases of pneumococcal disease (61%), 
pneumococcal-related deaths (67%) and the highest costs 
associated with this pathogenic agent (60%). 
In relation to what has just been said, it is evident that 
the current healthcare and financial burden of SP in adult 
age is essentially attributable to non-bacteriemic pneu-
monia, as also recently reported by other American au-
thors [8, 9].
In this respect, the impact of CAPs in adult age has been 
studied through several epidemiological surveys also 
within the European context, where the total annual rate 
ranged between 1.6 and 12/1000, including both hospi-
talized and non-hospitalized cases.
An interesting study conducted in Germany on a large 
national database including the entire adult population, 
based on the analysis of the hospital discharge chart 
including diagnoses for CAP (n = 388,406), related to 
2005 and 2006, showed a high annual incidence of these 
morbid forms, equal to 2.75 and 2.96/1000 inhabitants 
respectively, with mean values equal to 7.65/1000 in pa-
tients aged > 60 years [13]. 
These data are exactly in line with those of a previous 
American study, which observed an annual CAP inci-
dence in adult age equal to 2.67/1000 inhabitants [14]. In 
agreement with other previous investigations, CAP inci-
dence was strongly age-dependent, with the highest values 
reported in the over-80 elderly population (Fig. 2). These 
data have a great relevance for public health, in terms of 
healthcare impact, especially in view of the ageing of the 
population expected to occur in the near future in vari-
ous European countries and in the USA [15]. Further im-
portant information about this study involved mortality 
rates associated with CAPs, with a value of about 14%, 
this was found to be at a higher level than previously 
published (≤ 10%), since it could not be neglected even 
in low-risk subjects for their health conditions, already 
starting from the 50-59-year age group (Fig. 3). If, as 
we have already said, SP is considered the major CAP 
bacterial agent requiring hospitalisation of adults [16], 
these data clearly underline the need, from the view of 
public health, to improve prevention and control in the 
near future. 
The significant impact of CAPs, and specifically of 
those caused by SP, was shown, in terms of hospitali-
sations and deaths, also by another study published in 
2011 and conducted in Spain, where the hospital dis-
charge charts (ICD9 CM codes 480-486) of hospi-
talised patients aged ≥ 50 years were retrospectively 
evaluated on a national basis for a period of 5 con-
secutive years (2003-2007) [17]. Of the 447,670 all 
cause pneumonias identified, the SP ones were 17%, 
with annual hospitalisation rates respectively equal to 
6.27 and 1.09/1000, and deaths correlated to this were 
75,932 and 9,062. Also this study showed that the high-
est clinical impact of SP was age-dependent, where the 
elderly were those mostly affected, with an incidence 
of 23.30 cases/1000 and 4.21 cases/1000 of all cause 
pneumonias and of SPs, in the population group aged 
≥ 85 years. Similarly, the mortality and lethality rates 
increased with age, reaching peak values in those aged 
≥ 85 years equal to 5.51 deaths/1000 and 23.6% for all 
cause CAPs and equal to 0.73 deaths/1000 and 17.4% 
for those due to SP.
Unfortunately, in Italy there is no nationwide surveil-
lance system capable of producing an accurate estima-
tion of the clinical and health-
care impact of invasive and 
non-invasive diseases caused 
by SP and in relation to this, 
very few studies are available 
in literature that focus on the 
burden caused by pneumonias 
in the adult-elderly population.
A particularly interesting study 
was the one conducted by Gior-
gi Rossi et al. between 1997-
1999, by reviewing the hospital 
discharge charts, according to 
the ICD9-CM criteria, where 
the annual incidence of admis-
sions for CAPs was 1.58/1000 
in the adult population (lethality 
= 11.2%), rising up to 4.8/1000 
in individuals aged ≥ 65 years 
(lethality = 13.8%), with an av-
erage age upon admission of 65 
years (median = 70 years) [18]. 
Although in this study it was not 
possible to make an accurate es-
Fig. 2. incidence of hospitalised Community acquired pneumonias (Caps) in adults (per 1000), 
according to age groups, in a study based on the analysis of hospital discharge charts of a large 
european database (n= 388,406 cases monitored) (from ewig et al., 2009 [13], mod.).
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timation of the proportion of the 
invasive and non-invasive cases 
caused by SP, these results on 
the hospital admission rates per 
CAP were higher than those pre-
viously published regarding our 
national context [19], and per-
fectly matched those obtained 
by another study conducted in 
Spain, as previously discussed 
[10]. This evidence confirms 
that, in our country, CAPs are 
a morbid condition frequently 
found in the population, bur-
dened by a significant health-
care impact, not only in terms 
of access to healthcare services, 
but also of lethality, especially 
in the elderly, thus stating the 
need to urgently address this is-
sue as a public health priority.  
 
Capsular 
polysaccharide pneumococcal vaccine 
(PPV): state of the art 
Since the early 1980s, a 23-valent PPV for the preven-
tion of pneumococcal diseases has been available on the 
market. Current recommendations in Italy provide for 
its use in adults aged ≥ 65 years and in subjects, starting 
from the age of 2 years, affected by specific risk condi-
tions (i.e. chronic diseases of the cardiovascular, respi-
ratory and renal apparatus, anatomic and functional as-
plenia, conditions of immunosuppression, etc.) [20, 21]. 
The globally widespread use of PPV has been justified 
by the promising data obtained in terms of effectiveness 
against bacteremic pneumonias in clinical trials that had 
studied 13- and 14-valent polysaccharide vaccines, con-
taining 50µg of each capsular antigen. In 1977, the re-
sults of these studies led to the commercialization in the 
USA of a 14-valent polysaccharide vaccine, substituted 
in 1983 by the current PPV containing 25µg of each cap-
sule antigen, but without conducting new trials to evalu-
ate its immunogenicity and effectiveness profile.
In this context, PPV has been widely used in vaccine 
practice, principally in the USA, where about 60% of 
the elderly and 30% of adults “at risk” between the age 
of 50 and 65 years received one dose in 2007. Although 
significantly higher than the results of vaccine cover-
age achieved in our country, these rates remain however 
sub-optimal, especially in consideration of the fact that 
the recommendation to use PPV dates back to the early 
1980s. One of the reasons of the failure of PPV vacci-
nation strategies in adults is surely linked to the doubts 
around the protective efficacy and effectiveness of PPV 
that emerged from the analysis of the results obtained 
from clinical trials conducted in the last few years, both 
for the invasive forms in chronic patients, and, princi-
pally, for non-bacteriemic pneumonias and deaths. 
Fig. 3. distribution of in-patient mortality among adults admitted for Community acquired 
pneumonia (Cap), according to age groups, in a study based on the analysis of hospital dis-
charge charts of a large european database (n = 388,406 cases monitored) (from ewig et al., 
2009 [13], mod.).
At least in part, these gaps have been ascribed to the 
proven sub-optimal ability of all non-conjugate polysac-
charide vaccines of inducing an adequate immunologi-
cal response and, above all, in maintaining it over time. 
In fact, it is renown that capsular polysaccharides con-
tained in PPV are able to elicit, through a T-independent 
type mechanism, the simple differentiation of plasma 
cell populations with a short half-life, in charge of pro-
ducing direct antibodies against capsular antigens of SP, 
principally of class IgG2 [22]. However, PPV is unable 
to trigger the creation of an immunological memory, be-
cause this is a T-dependent process. This has important 
implications in terms of duration of protection in that 
follow primary immunization and of the actual utility of 
vaccine boosters, although, for PPV, it has been shown 
how subsequent doses of vaccine are unable to achieve a 
better immune response, if not even worse, than the one 
obtained with priming [22]. In relation to this, the rec-
ommendations in force in Italy, in agreement with what 
was stated in a recent position paper of the WHO, pro-
vide for a single re-vaccination with PPV at a distance of 
5 years from the administration of the first dose, where-
as, a more recent recommendation in the USA by the 
Advisory Committee on Immunization Practices (ACIP) 
provides for re-vaccination only in high-risk subjects be-
tween the age of 19-64 years (e.g. affected by anatomic 
or functional asplenia and immunosuppressed) [23, 24]. 
As mentioned before, the interpretation of the results 
linked to the efficacy and effectiveness profile of PPV, 
in the light of the many studies conducted in the last 30 
years, is still controversial today, even in consideration 
of some differences in terms of categories of enrolled 
subjects and clinical outcomes used by various research 
studies. This has been further complicated by some im-
portant methodological limitations of randomized con-
trolled trials that evaluate effectiveness (e.g. randomi-
g. iCardi et al.
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zation methods, study blindness), highlighted in recent 
meta-analyses, as well as selection bias and confounding 
factors that are integral to observational studies adopted 
to evaluate effectiveness. Moreover, it is renown that 
many factors contribute to make it difficult to evaluate 
the effectiveness of the vaccine concerned, in particu-
lar (i) the low frequency of the mostly specific outcome 
(the invasive pathology), (ii) the poor accuracy and 
non-uniqueness of the diagnostic criteria adopted for 
the CAP outcomes and finally (iii) the variability of the 
vaccine’s effectiveness in relation to the age factor and 
to the severity of the pathological conditions associated 
with a higher risk of developing pneumococcal disease 
in the subjects being monitored.
Tables I and II illustrate the characteristics and the re-
sults of the efficacy of the main randomized controlled 
trials and non-randomized clinical studies conducted 
with PPV in adults. 
With regard to this, two interesting meta-analyses con-
ducted by the Cochrane Collaboration group have recently 
analysed the results reported in literature and considered 
them methodologically well designed [25, 26].
The first meta-analysis evaluated the results of 15 rand-
omized controlled trials (n = 48,656 participants) and of 7 
non-randomized controlled trials (n = 62,294 participants) 
on adults. In the randomized controlled trials, a strong ev-
idence of PPV efficacy had been proven against invasive 
diseases (74%, 95% CI: 56-85; I-squared = 0%), whereas 
data analysed in relation to all cause pneumonias were 
found to be inconclusive, with a substantial heterogene-
ity from a statistical point of view (29%, 95% CI: 3-48; 
I-squared = 87.3%) [25]. In addition, the use of PPV did 
not determine any significant reduction of all cause mor-
tality in the population included in the studies [25]. Those 
who benefited most of the positive effects of the vaccine 
were mainly the younger adults in good health condi-
tions, yet [23]. Insufficient results were mainly found in 
the high risk populations, like adults affected by specific 
morbid conditions and immunosuppressed individuals 
of all ages, with PPV protective efficacy values equal to 
-56% (95% CI: -6.94 – 65) against invasive diseases and 
equal to 3% (95% CI: -1.46 – 35) versus pneumonias. 
With regard to the non-randomized trials, PPV efficacy 
in the prevention of invasive diseases ranged between 
26-70% in immunocompetent adults and in subjects with 
underlying pathological conditions, but not immunocom-
promised, with a global value of 52% (95% CI: 39-63; 
I-squared = 31.4%) [25].
The second meta-analysis evaluated the efficacy of PPV 
in patients suffering from Chronic Obstructive Pulmo-
nary Disease (COPD): only 7 randomized controlled 
trials published in the literature met the inclusion cri-
teria for this review, that considered the prevention of 
pneumonia (n = 1372 patients examined) and COPD 
acute re-exacerbation (n = 216 patients examined) as 
the primary outcomes of analysis. Results did not allow 
Tab. I. Characteristics and results of the main randomized controlled trials evaluating the efficacy of polysaccharide anti-pneumococcal vac-
cines in adults.
Authors Year Sample 
dimension
Characteristic 
of participants
Follow up 
(months)
Number of 
serotypes 
contained in the 
vaccine
Effectiveness (%)
ipd
Npp
austrian et al. 1976 4.500 miners 24 6/13 55 45
smit et al. 1977 4.694 miners 24 6/12 na 38
riley et al. 1977 11.958
adults from tari in papua New 
guinea highlands
16 14 75* 15*
austrian et al. 1980 1300 patients of mental hospital 36 12 na -5*
austrian et al. 1980 13.600 adults aged ≥ 45 years 30 12 na 11*
gaillat et al. 1985 1.686 adults aged ≥ 55 years 24 14 na 63
Klastersky 
et al.
1986 50
patients with bronchogenic 
carcinoma
12 17 10* na
simberkoff 
et al.
1986 2.295 high risk patients aged ≥ 55 years 35 14 0 -28*
davis et al. 1987 103
adults with chronic obstructive 
pulmonary disease
24 14 na 13*
Koivula et al. 1997 2.837 adults aged ≥ 60 years 36 14 na -17*
Ortqvist et al. 1998 691
Non-immunocompromised 
adults aged 50 to 85 years 
who had been inpatients for 
community acquired
pneumonia
32 23 65* -17*
alfageme 
et al.
2006 596
adults with chronic obstructive 
pulmonary disease
36 23
na
24
na: data not available; ipd: invasive pneumococcal disease; Npp: Nonbacteremic pneumococcal pneumonia; * no statistical significance
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to determine any benefit from PPV, because it was not 
possible to detect statistically significant differences be-
tween the intervention and control groups. In fact, the 
protective effectiveness of the vaccine was estimated to 
be equal to 28% (95% CI -1 – 49) and to 42% (95% CI 
-13 -70) against pneumonias and COPD acute re-exac-
erbations [26]. 
Conclusions and perspectives  
with the second generation  
of pneumococcal conjugate vaccines
In the light of what has been said, it is evident (i) on one 
hand, the still significant burden of SP disease in adults-
elderly in Western countries, and (ii) on the other, some 
limits of PPV in terms of protection against invasive 
diseases, among adults affected with chronic diseases, 
non-bacteriemic pneumonias, the clinical picture with a 
higher incidence and healthcare impact on the popula-
tion, and all-cause mortality.
The recent availability on the market, as well as PPV, 
of a second generation of pneumococcal conjugate vac-
cines for adults aged > 50 years [27], having an ade-
quate safety and immunogenicity profile and, hopeful-
ly, determining a long-lasting protection against both 
invasive and non-invasive pneumococcal diseases, 
opens up new interesting perspectives to control this 
important health issue in the Western countries, espe-
cially in the elderly and high risk subjects of all ages. In 
the next future, further studies on pneumococcal vacci-
nation efficacy and effectiveness are warranted in these 
target groups.
Furthermore, the availability of national data on the eco-
logical scenario of SP and its clinical impact among adult 
and elderly population, in terms of admissions, mortality 
and lethality, as well as to estimate the subsequent bur-
den for the society, in terms of costs and consumption 
of healthcare resources available, will offer better guid-
ance to public health decision-makers when developing 
future vaccination strategies.
Tab. II. Characteristics and results of the main non-randomized trials evaluating the efficacy of polysaccharide anti-pneumococcal vaccines in 
adults.
Authors Year Sample 
dimension
Characteristic 
of participants
Study Method Number of 
serotypes 
contained in 
the vaccine
IPD NPP
shapiro et al. 1984 90/90
adults aged ≥ 18 years with 
indication for vaccination or 
aged ≥ 65 years
Case-control
14 67 na
sims et al. 1988 122/244
immunocompetent older 
adults aged ≥ 55 years
Case-control Not specified
70 (37- 86)
na
shapiro et al. 1991 1.054/1.054
adults aged ≥ 18 years with 
indication for vaccination or 
aged ≥ 65 years
Case-control 14 o 23 47 (30-59) na
Benin et al. 2003 108/330
adults aged ≥ 18 years with 
indication for vaccination or 
aged ≥ 65 years
Case-control 23
26 (−29-58)
na
Jackson et al. 2003 47.365
adults aged ≥ 65 years 
(follow-up 3 years)
Cohort 23 44 (7-67)
- 4 (-13- 4)
dominguez 
et al.
2005 149/447
adults hospitalised with 
invasive pneumococcal 
disease aged ≥65 years
Case-control 23 70 (48-82)
na
vila-Corcoles 
et al.
2006 11.241
adults aged ≥ 65 years 
(follow-up 3 years)
Cohort 23 40 (-65-88) 21 (2-36)
na: data not available; ipd: invasive pneumococcal disease; Npp: Nonbacteremic pneumococcal pneumonia
References
[1] Health Protection Agency. Centre for Infections, London, UK. 
Invasive Pneumococcal Disease (IPD) in England & Wales 
after 7-valent conjugate vaccine (PCV7); potential impact of 
10 and 13-valent vaccines. Available at http://www.hpa.org.uk/
web/HPAwebFile/HPAweb_C/1245581527892.
[2] Weycker D, Strutton D, Edelsberg J, et al. Clinical and econom-
ic  burden of pneumococcal disease in older US adults. Vaccine 
2010;28:4955-60.
[3] Pilishvili T, Lexau C, Farley M, et al. Sustained reductions in 
invasive pneumoccoal disease in the era of conjugate vaccine. J 
Inf Dis 2010;201:302-41.
[4] Durando P, Crovari P, Ansaldi F, et al. Universal childhood 
immunisation against Streptococcus pneumoniae: the five-year 
experience of Liguria Region, Italy. Vaccine 2009;27:3459-62.
g. iCardi et al.
84
[5] Lexau CA, Lynfield R, Danila R, et al. Changing epidemiol-
ogy of invasive pneumococcal disease among older adults in 
the era of pediatric pneumococcal conjugate vaccine. JAMA 
2005;294:2043-51. 
[6] Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneu-
monia admissions after routine childhood immunisation with 
pneumococcal conjugate vaccine in the USA: a time-series 
analysis. Lancet 2007;369:1179-86.
[7] Resti M, Micheli A, Moriondo M, et al. Comparison of the 
effect of antibiotic treatment on the possibility of diagnos-
ing invasive pneumococcal disease by culture or molecular 
methods: a prospective, observational study of children and 
adolescents with proven pneumococcal infection. Clin Ther 
2009;31:1266-73.
[8] Nelson JC, Jackson M, Yu O, et al. Impact of the introduc-
tion of pneumococcal conjugate vaccine on rates of commu-
nity acquired pneumonia in children and adults. Vaccine 2008; 
26:4947-54.
[9] Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization 
and cost of pneumococcal disease in the United States. Vaccine 
2011; 29:3398-412.
[10] Almirall J, Bolíbar I, Vidal J, et al. Epidemiology of community-
acquired pneumonia in adults: a population-based study. Eur 
Respir J 2000;15:757-63. 
[11] Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of commu-
nity-acquired pneumonia in the population of four municipali-
ties in eastern Finland. Am J Epidemiol 1993;137:977-88.
[12] Gutiérrez F, Masiá M, Mirete C, et al. The influence of age 
and gender on the population-based incidence of community-
acquired pneumonia caused by different microbial pathogens. J 
Infect 2006;53:166-74.
[13] Ewig S, Birkner N, Strauss R, et al. New perspectives on com-
munity-acquired pneumonia in 388406 patients. Results from a 
nationwide mandatory performance measurement programme 
in healthcare quality. Thorax 2009;64:1062-9.
[14] Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of com-
munity-acquired pneumonia requiring hospitalization. Results 
of a population-based active surveillance Study in Ohio. The 
Community-Based Pneumonia Incidence Study Group. Arch 
Intern Med 1997;157:1709-18.
[15] Jackson ML, Neuzil KM, Thompson WW, et al. The burden of 
community-acquired pneumonia in seniors: results of a popula-
tion-based study. Clin Infect Dis 2004;39:1642-50.
[16] Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: 
Plotkin SA, Orenstein WA, eds. Vaccines. Vol. 25, 3rd ed. Phila-
delphia: WB Saunders 1999, pp. 215-219.
[17] Gil-Prieto R, García-García L, Alvaro-Meca A, et al. The bur-
den of hospitalisations for community-acquired pneumonia 
(CAP) and pneumococcal pneumonia in adults in Spain (2003-
2007). Vaccine 2011;29:412-6.
[18] Giorgi Rossi P, Agabiti N, Faustini A, et al. The burden of hos-
pitalized pneumonia in Lazio, Italy, 1997-1999. Int J Tuberc 
Lung Dis 2004;8:528-36.
[19] D’Alessandro D, Cerquetani F, Proietti F, et al. Andamento 
della mortalità per polmoniti in Italia nel periodo 1975-1994. 
Ann Ig 1999;11:251-260.
[20] Ministero della Salute. Circolare n. 11 del 19 Novembre 2001. 
Vaccinazione antipneumococcica in età pediatrica. 
[21] Ministero della Salute. Circolare del 29 Luglio 2010. Circolare 
Prevenzione e controllo dell’influenza: raccomandazioni per la 
stagione 2010-2011.
[22] French N. Use of pneumococcal polysaccharide vaccines: no 
simple answers. J Infect 2003;46:78-86. 
[23] WHO position paper. 23-valent pneumococcal polysaccharide 
vaccine. Wkly Epidemiol Rec 2008;83:373-84.
[24] Centers for Disease Control and Prevention (CDC); Advi-
sory Committee on Immunization Practices. Updated recom-
mendations for prevention of invasive pneumococcal disease 
among adults using the 23-valent pneumococcal polysac-
charide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 
2010;59:1102-6. 
[25] Moberley SA, Holden J, Tatham DP, et al. Vaccines for pre-
venting pneumococcal infection in adults. Cochrane Database 
Syst Rev 2008;(1):CD000422.
[26] Walters JA, Smith S, Poole P, et al. Injectable vaccines for 
preventing pneumococcal infection in patients with chronic 
obstructive pulmonary disease. Cochrane Database Syst Rev 
2010;(11):CD001390. 
[27] European Medicines Agency (EMA). Available at http://www.
ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/
medicines/001104/smops/Positive/human_smop_000294.
jsp&mid=WC0b01ac058001d127.
n	 Received on February 24, 2012. Accepted on March 30, 2012.
n	 Correspondence: P. Durando, Department of Health Sciences, 
Section of Hygiene and Preventive Medicine, Vaccines and Clini-
cal Trials Unit, San Martino Hospital, University of Genoa, via A. 
Pastore 1, 16132 Genoa, Italy - E-mail: durando@unige.it
